

- [83] WHO. Initiative for Vaccine Research, WHO, Proceedings of the 7th Global Vaccine Research Forum. Bangkok; 2006.
- [132] Parashar UD, Bresee JS, Glass RI. The global burden of diarrhoeal disease in children. *Bull World Health Organ* 2003;81:236.
- [133] Widdowson MA, Bresee JS, Gentsch JR, Glass RI. Rotavirus disease and its prevention. *Curr Opin Gastroenterol* 2005;21:26-31.
- [134] Perez N. Rotavirus gastroenteritis: why to back up the development of new vaccines? *Comp Immunol Microbiol Infect Dis* 2008;31:253-69.
- [135] Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. *Emerg Infect Dis* 2006;12:304-6.
- [136] Gleizes O, Desselberger U, Tatochenko V, Rodrigo C, Salman N, Mezner Z, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. *Pediatr Infect Dis J* 2006;25:S12-21.
- [137] Dennehy PH, Cortese MM, Begue RE, Jaeger JL, Roberts NE, Zhang R, et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children. *Pediatr Infect Dis J* 2006;25:1123-31.
- [138] Anderson EJ, Weber SG. Rotavirus infection in adults. *Lancet Infect Dis* 2004;4:91-9.
- [139] Marshall J, Botes J, Gorrie G, Boardman C, Gregory J, Griffith J, et al. Rotavirus detection and characterisation in outbreaks of gastroenteritis in aged-care facilities. *J Clin Virol* 2003;28:331-40.
- [140] Fischer TK, Bresee JS, Glass RI. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. *Vaccine* 2004;22 Suppl 1:S49-54.
- [141] Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. *Emerg Infect Dis* 2003;9:565-72.
- [142] Bresee J, Fang ZY, Wang B, Nelson EA, Tam J, Soenarto Y, et al. First report from the Asian Rotavirus Surveillance Network. *Emerg Infect Dis* 2004;10:988-95.
- [143] Molbak K, Fischer TK, Mikkelsen CS. The estimation of mortality due to rotavirus infections in sub-Saharan Africa. *Vaccine* 2000;19:393-5.
- [144] Schwartz-Cornil I, Benureau Y, Greenberg H, Hendrickson BA, Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. *J Virol* 2002;76:8110-7.
- [145] Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. *Rev Med Virol* 2005;15:29-56.
- [146] Hoshino Y, Kapikian AZ. Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. *J Health Popul Nutr* 2000;18:5-14.
- [147] Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. *Vaccine* 2003;21:361-7.
- [148] Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. *J Infect Dis* 2005;192 Suppl 1:S160-6.
- [149] Salinas B, Perez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. *Pediatr Infect Dis J* 2005;24:807-16.
- [150] Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus

- gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. *Lancet* 2008; 371:1181-9.
- [151] Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *N Engl J Med* 2006;354 :11-22.
- [152] Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. *N Engl J Med* 1983;309:72-6.
- [153] Barnes GL, Lund JS, Mitchell SV, De Bruyn L, Piggford L, Smith AL, et al. Early phase II trial of human rotavirus vaccine candidate RV3. *Vaccine* 2002;20: 2950-6.
- [154] Midthun K, Kapikian AZ. Rotavirus vaccines: an overview. *Clin Microbiol Rev* 1996;9:423-34.
- [155] Dennehy PH. Rotavirus vaccines: an update. *Curr Opin Pediatr* 2005;17: 88-92.
- [156] Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. *J Infect Dis* 2006;194:370-6.
- [157] CDC. Withdrawal of rotavirus vaccine recommendation. *MMWR, Morb Mortal Wkly Rep* 1999;48:1007.
- [158] Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. *N Engl J Med* 2006;354:23-33.
- [159] Rodriguez ZM, Goveia MG, Stek JE, Dallas MJ, Boslego JW, DiNubile MJ, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. *Pediatr Infect Dis J* 2007;26:221-7.
- [160] Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. *Vaccine* 2006;24:5817-23.
- [161] Banerjee I, Gladstone BP, Le Fevre AM, Ramani S, Iturriza-Gomara M, Gray JJ, et al. Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. *J Infect Dis* 2007;195:625-32.
- [162] Johansen K, Schroder U, Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. *Vaccine* 2003;21:368-75.
- [163] Herrmann JE. DNA vaccines against enteric infections. *Vaccine* 2006;24:3705-8.
- [164] Choi AH, Smiley K, Basu M. Induction of immune responses and partial protection in mice after skin immunization with rotavirus VP6 protein and the adjuvant LT(R192G). *Vaccine* 2005;23:2290-3.
- [165] McNeal MM, Stone SC, Basu M, Bean JA, Clements JD, Hendrickson BA, et al. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. *Virology* 2006;346:338-47.
- [166] Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. *Vaccine* 2003;21:3885-900.
- [167] Blutt SE, Warfield KL, O'Neal CM, Estes MK, Conner ME. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). *Vaccine* 2006;24:1170-9.

- [\[168\]](#) Parez N, Fourgeux C, Mohamed A, Dubuquoy C, Pillot M, Dehee A, et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. *J Virol* 2006;80:1752-61.
- [\[169\]](#) Glass RI, Bresee J, Jiang B, Parashar U, Yee E, Gentsch J. Rotavirus and rotavirus vaccines. *Adv Exp Med Biol* 2006;582:45-54.
- [\[170\]](#) Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent developments and future considerations. *Nat Rev Microbiol* 2007;5:529-39.
- [\[171\]](#) Dennehy PH. Rotavirus vaccines--an update. *Vaccine* 2007;25:3137-41.
- [\[172\]](#) CDC. Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007-May 2008. *MMWR Morb Mortal Wkly Rep* 2008;57:697-700.